Purpose Research describing proctitis or pelvic radiation disease symptoms of prostate cancer patients one year after external beam radiotherapy (EBRT) plus high-dose-rate (HDR) brachytherapy is limited. This study aimed to assess prostate cancer patients' pelvic radiation disease symptoms from baseline to 12 months post-radiotherapy. Material and methods Men with prostate cancer referred for...

abstract prostate cancer is one of the life threatening disorders of male. although, over the last two decades, a high rate of overdiagnosis, and overtreatment has lowered the incidence rate of prostate cancer, the treatment or prevention strategies are not enough to control the high rate of disease related mortality. current medical treatment approaches include surgery, radiation therapy, chem...

introduction: recently, magnetic resonance spectroscopic imaging (mrsi), as a functional imaging method, has been used for clinical target volume definition. in this study, we used this method to define the target volume in prostate radiotherapy. material and method: in this study, we used images of 20 prostate cancer cases. mrsi and mri images were fused with ct images. then, treatment plannin...

The immune system plays a complementary role in the cytotoxic activity of radiotherapy. Here, we examined changes in immune cell subsets after heavy ion therapy for prostate cancer. The lymphocyte counts were compared with acute radiotherapy-related toxicity, defined according to the Common Terminology Criteria for Adverse Events, and short-term local efficacy, defined based on prostate-specifi...

Indium-111 radioimmunoscintigraphy (RIS) has an increasing role in the treatment of prostate cancer and is most commonly performed at this disease site using labeled monoclonal antibody against prostate-specific membrane antigen. There are many limitations of RIS, including low spatial resolution, low diagnostic yield and limited availability. Despite these limitations, the efficacy of RIS has ...

Historical data for older men with high-risk nonmetastatic prostate cancer treated with radiotherapy alone have demonstrated a 10-year prostate-cancer-specific mortality of around 30%. The development of dose escalation, using techniques such as intensity-modulated radiotherapy, has enabled more targeted delivery of treatment with improved efficacy and a reduction in the risk of toxicity compar...

BACKGROUND The aim of the present study was to evaluate the prevalence and severity of lower limb lymphedema after pelvic lymphadenectomy and radiotherapy to the pelvic lymph nodes in patients with prostate cancer. METHODS Twenty-six patients underwent combined treatment for high-risk node-positive prostate cancer at Skåne University Hospital between April 2008 and March 2011. The treatment c...

PURPOSE/OBJECTIVES Treatment of the primary tumor reportedly improves survival in several types of metastatic cancer. We herein evaluated the efficacy and toxicity of radiotherapy for the primary tumor in prostate cancer with metastasis. MATERIALS/METHODS The study cohort included 140 men with metastatic prostate cancer at initial diagnosis. Metastatic sites were divided into 4 groups as foll...

Introduction: Radiotherapy is one of the treatment options for locally advanced prostate cancer, however with standard radiation doses it is not always very effective. One of the strategies to improve the efficiency of radiotherapy is increasing the dose. In this study to increase tumor local control rates a new radiotherapy method, known as dose painting (DP) was investigated....